Paper20948438
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
Louis CU and 14 others. J Immunother, 2010. Cited by 187 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. Papers, record 20948438. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20948438
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
- PubMed
- Publication types
- Clinical Trial, Phase I, Clinical Trial, Phase II, Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma | Major topic |
| Herpesvirus 4, Human | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Nasopharyngeal Neoplasms | Major topic |
| T-Lymphocytes, Cytotoxic | Major topic |
| Adolescent | |
| Adult | |
| Antigens, Viral | |
| Cell Proliferation | |
| Child | |
| Disease Progression | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasm Recurrence, Local | |
| Prognosis | |
| Treatment Outcome |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K01 RR000188 | NCRR NIH HHS | United States | K01RR000188 | PubMed and NIH | NIH RePORTER |
| T32 DK64717 | NIDDK NIH HHS | United States | T32DK064717 | PubMed and NIH | NIH RePORTER |
| M01 RR000188 | NCRR NIH HHS | United States | K01RR000188 | PubMed and NIH | NIH RePORTER |
| K12 CA09043306 | NCI NIH HHS | United States | K12CA090433 | PubMed and NIH | NIH RePORTER |
| K12 CA090433 | NCI NIH HHS | United States | K12CA090433 | PubMed and NIH | NIH RePORTER |
| P01 CA094237 | NCI NIH HHS | United States | P01CA094237 | PubMed and NIH | NIH RePORTER |
| P01 CA94237 | NCI NIH HHS | United States | P01CA094237 | PubMed and NIH | NIH RePORTER |
| RR00188 | NCRR NIH HHS | United States | K01RR000188 | PubMed and NIH | NIH RePORTER |
| T32 DK064717 | NIDDK NIH HHS | United States | T32DK064717 | PubMed and NIH | NIH RePORTER |
| M01RR000188 | NIH | NIH RePORTER |
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00609219 | T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | Background | ClinicalTrials.gov | |
| NCT02421640 | Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC | Background | ClinicalTrials.gov | |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | Background | ClinicalTrials.gov |
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11018123 | Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. | Annu Rev Microbiol | 2000 | https://conductscience.org/library/papers/11018123 | PubMed |
| 2 | 19211798 | Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19211798 | PubMed |
| 3 | 18354418 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18354418 | PubMed |
| 4 | 15611290 | Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. | J Exp Med | 2004 | https://conductscience.org/library/papers/15611290 | PubMed |
| 5 | 11912175 | Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. | Cancer Res | 2002 | https://conductscience.org/library/papers/11912175 | PubMed |
| 6 | 12427970 | Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/12427970 | PubMed |
| 7 | 15809453 | Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15809453 | PubMed |
| 8 | 17609424 | Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. | Blood | 2007 | https://conductscience.org/library/papers/17609424 | PubMed |
| 9 | 10655437 | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10655437 | PubMed |
| 10 | 12411306 | Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. | Blood | 2003 | https://conductscience.org/library/papers/12411306 | PubMed |
| 11 | 18213730 | Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. | Head Neck | 2008 | https://conductscience.org/library/papers/18213730 | PubMed |
| 12 | 16951192 | Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. | Cancer Res | 2006 | https://conductscience.org/library/papers/16951192 | PubMed |
| 13 | 17909810 | Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. | Cancer Chemother Pharmacol | 2008 | https://conductscience.org/library/papers/17909810 | PubMed |
| 14 | 12181249 | Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. | Ann Oncol | 2002 | https://conductscience.org/library/papers/12181249 | PubMed |
| 15 | 9716582 | Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. | Blood | 1998 | https://conductscience.org/library/papers/9716582 | PubMed |
| 16 | 12167421 | A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. | Oral Oncol | 2002 | https://conductscience.org/library/papers/12167421 | PubMed |
| 17 | 15612023 | Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. | Cancer | 2005 | https://conductscience.org/library/papers/15612023 | PubMed |
| 18 | 11159505 | An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. | Blood | 2001 | https://conductscience.org/library/papers/11159505 | PubMed |
| 19 | 16148164 | Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. | J Immunol | 2005 | https://conductscience.org/library/papers/16148164 | PubMed |
| 20 | 20222940 | Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome. | Radiat Oncol | 2010 | https://conductscience.org/library/papers/20222940 | PubMed |
Cited by126
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42752793 | Nasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and management. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42752793 | PubMed |
| 42700448 | CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects. | Rev Med Virol | 2026 | https://conductscience.org/library/papers/42700448 | PubMed |
| 42695022 | Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review. | Lancet Reg Health West Pac | 2026 | https://conductscience.org/library/papers/42695022 | PubMed |
| 42510669 | Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42510669 | PubMed |
| 42389513 | Epstein-Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics. | Front Immunol | 2026 | https://conductscience.org/library/papers/42389513 | PubMed |
| 42195319 | Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42195319 | PubMed |
| 42193922 | Natural Killer (NK) Cells in Tumor Immunity: Limitations and Therapeutic Potential with a Focus on Nasopharyngeal Carcinoma and Comparison with T-Cell-Based Therapies. | Cells | 2026 | https://conductscience.org/library/papers/42193922 | PubMed |
| 42180045 | Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges. | Front Oncol | 2026 | https://conductscience.org/library/papers/42180045 | PubMed |
| 41750326 | Nasopharyngeal Carcinoma at the Virology Precision Oncology Nexus: Decoding Molecular Alterations for Early Intervention and Therapeutic Innovation. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750326 | PubMed |
| 40844293 | Adoptive T-cell therapy for virus-associated diseases. | Clin Microbiol Rev | 2025 | https://conductscience.org/library/papers/40844293 | PubMed |
| 40563634 | The Role of Viruses in the Glioma Tumor Microenvironment: Immunosuppressors or Primers for Anti-Tumor Immunity? | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40563634 | PubMed |
| 40401927 | Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions. | J Cell Mol Med | 2025 | https://conductscience.org/library/papers/40401927 | PubMed |
| 40191756 | The role and mechanism of aerobic glycolysis in nasopharyngeal carcinoma. | PeerJ | 2025 | https://conductscience.org/library/papers/40191756 | PubMed |
| 39450176 | Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies. | Front Immunol | 2024 | https://conductscience.org/library/papers/39450176 | PubMed |
| 39338919 | Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review. | Pathogens | 2024 | https://conductscience.org/library/papers/39338919 | PubMed |
| 38888489 | Characterization of unique pattern of immune cell profile in patients with nasopharyngeal carcinoma through flow cytometry and machine learning. | J Cell Mol Med | 2024 | https://conductscience.org/library/papers/38888489 | PubMed |
| 38815238 | Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses. | Blood Adv | 2024 | https://conductscience.org/library/papers/38815238 | PubMed |
| 38755255 | Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/38755255 | PubMed |
| 38023360 | Precision drugs for recurrent or metastatic nasopharyngeal carcinoma (Review). | Exp Ther Med | 2023 | https://conductscience.org/library/papers/38023360 | PubMed |
| 37932756 | Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect. | J Transl Med | 2023 | https://conductscience.org/library/papers/37932756 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD27 | 939 | PubTator's text mining | https://conductscience.org/library/genes/939 | NCBI Gene |
| CD28 | 940 | PubTator's text mining | https://conductscience.org/library/genes/940 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| FCGR3A | 2214 | PubTator's text mining | https://conductscience.org/library/genes/2214 | NCBI Gene |
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| NCAM1 | 4684 | PubTator's text mining | https://conductscience.org/library/genes/4684 | NCBI Gene |
| PSMB9 | 5698 | PubTator's text mining | https://conductscience.org/library/genes/5698 | NCBI Gene |
| PTPRC | 5788 | PubTator's text mining | https://conductscience.org/library/genes/5788 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20948438
GET https://conductscience.org/api/papers/v1/20948438/references?page=2